Evidence map›Paper›PMID 37031458›Full record

ArticleCancer medicine2023

A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients.

Juliana Muller Bark, Avinash V Karpe, James D Doecke, Paul Leo, Rosalind L Jeffree, Benjamin Chua, Bryan W Day, David J Beale, Chamindie Punyadeera

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Juliana Muller BarkFaculty of Health, Centre for Biomedical Technologies, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.ORCID 0000-0003-0291-0094
Avinash V KarpeEnvironment, Commonwealth Scientific and Industrial Research Organization (CSIRO), Ecosciences Precinct, Dutton Park, Queensland, Australia.
James D DoeckeAustralian eHealth Research Centre, CSIRO. Level 7, Surgical Treatment and Rehabilitation Service - STARS, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
Paul LeoFaculty of Health, School of Biomedical Sciences, Queensland University of Technology, Gardens Point, Queensland, Australia.
Rosalind L JeffreeQIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Benjamin ChuaFaculty of Medicine, University of Queensland, Herston, Queensland, Australia.
Bryan W DayFaculty of Health, School of Biomedical Sciences, Queensland University of Technology, Gardens Point, Queensland, Australia.
David J BealeEnvironment, Commonwealth Scientific and Industrial Research Organization (CSIRO), Ecosciences Precinct, Dutton Park, Queensland, Australia.
Chamindie PunyadeeraSaliva and Liquid Biopsy Translational Laboratory, Griffith Institute for Drug Discovery - Griffith University, Brisbane, Queensland, Australia.ORCID 0000-0001-9039-8259
Commonwealth Scientific and Industrial Research Organisation · AUGriffith University · AUThe University of Queensland · AUQueensland University of Technology · AUTranslational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite aggressive treatment, more than 90% of glioblastoma (GBM) patients experience recurrences. GBM response to therapy is currently assessed by imaging techniques and tissue biopsy. However, difficulties with these methods may cause misinterpretation of treatment outcomes. Currently, no validated therapy response biomarkers are available for monitoring GBM progression. Metabolomics holds potential as a complementary tool to improve the interpretation of therapy responses to help in clinical interventions for GBM patients.

methodsSaliva and blood from GBM patients were collected pre and postoperatively. Patients were stratified conforming their progression-free survival (PFS) into favourable or unfavourable clinical outcomes (>9 months or PFS ≤ 9 months, respectively). Analysis of saliva (whole-mouth and oral rinse) and plasma samples was conducted utilising LC-QqQ-MS and LC-QTOF-MS to determine the metabolomic and lipidomic profiles. The data were investigated using univariate and multivariate statistical analyses and graphical LASSO-based graphic network analyses.

resultsAltogether, 151 metabolites and 197 lipids were detected within all saliva and plasma samples. Among the patients with unfavourable outcomes, metabolites such as cyclic-AMP, 3-hydroxy-kynurenine, dihydroorotate, UDP and cis-aconitate were elevated, compared to patients with favourable outcomes during pre-and post-surgery. These metabolites showed to impact the pentose phosphate and Warburg effect pathways. The lipid profile of patients who experienced unfavourable outcomes revealed a higher heterogeneity in the abundance of lipids and fewer associations between markers in contrast to the favourable outcome group.

conclusionOur findings indicate that changes in salivary and plasma metabolites in GBM patients can potentially be employed as less invasive prognostic biomarkers/biomarker panel but validation with larger cohorts is required.

Indexed as

Brain NeoplasmsGlioblastomaBiomarkersHumansLipidsMetabolomicsPilot ProjectsSalivaBiomarkersLipidsbloodglioblastomalipidsmetabolitesmetabolomicssaliva

Identifiers

PMID37031458
PMCPMC10242862
OpenAlexW4362724476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.